MedPage Today
MedPage's roundup also notes GLP-1 use among Medicare patients with type 2 diabetes rose more than 16-fold from 2010 to 2022, and L'Oréal building skincare for rapid weight loss.
Recap by typeshit. Full story at MedPage Today.
An investing platform's company history runs from Lilly's 1876 founding through Humulin and Prozac to its obesity drug boom. Background, not news.
Generic advice that a lack of hunger doesn't mean you've eaten enough, with a nudge toward smaller portions built around protein.
Dr. Mimi Tan points to a wider set of obesity treatments and notes Ozempic is the semaglutide brand meant for type 2 diabetes.
Brian Underwood shares that the Men's Health fall issue starring Drake Maye is on newsstands, with peptides among the topics inside.
The account argues accidental overdoses usually trace back to dosing errors, and links the problem to approved GLP-1 drugs costing over $1,000 a month uninsured.
31:59
A video rundown of what Eli Lilly's late-stage retatrutide trial data shows for people following the drug.
Loading…